Search results
Results from the WOW.Com Content Network
Devimistat (INN; development code CPI-613) is an experimental anti-mitochondrial drug being developed by Cornerstone Pharmaceuticals. [1] It is being studied for the treatment of patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML).
The H 2 receptor antagonists are a class of drugs used to block the action of histamine on parietal cells in the stomach, decreasing the production of acid by these cells. H 2 antagonists are used in the treatment of dyspepsia, although they have been surpassed in popularity by the more effective [1] proton pump inhibitors.
6-Diazo-5-oxo-L-norleucine (DON) is a glutamine antagonist, which was isolated originally from Streptomyces in a sample of Peruvian soil.This diazo compound is biosynthesized from lysine by three enzymes in bacteria. [2]
Acidic refractories are generally impervious to acidic materials but easily attacked by basic materials, and are thus used with acidic slag in acidic environments. They include substances such as silica , alumina , and fire clay brick refractories.
The FDA has, however, approved VNS to treat refractory (drug-resistant) epilepsy, drug-resistant depression, cluster headache, migraine, and stroke recovery. Meanwhile, VNS is being investigated ...
Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not effective or are not tolerated. [2] The drug is administered by infusion intravenously. Since October 2023, Amgen Inc. has been the marketer of pegloticase in ...
The safety and effectiveness of elranatamab was evaluated in MagnetisMM-3 (NCT04649359), an open-label, single-arm, multi-center study that included participants with relapsed/refractory multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody. [12]
Cimetidine was the prototypical histamine H 2 receptor antagonist from which later drugs were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist that would suppress stomach acid secretion.